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The B-Raf proto-oncogene serine/threonine kinase (B-Raf) is a member of the Raf kinase family. The BRAF V600E
mutation occurs frequently in certain brain tumors such as pleomorphic xanthoastrocytoma, ganglioglioma, and
pilocytic astrocytoma, and less frequently in epithelioid and giant cell glioblastoma. BRAF V600E mutation in these
cases has been canonically detected using Sanger sequencing or immunohistochemistry but not with next-generation
sequencing (NGS). Moreover, to our knowledge, there is no detailed report of the BRAF V600E mutation in an adult
glioblastoma with classical histologic features (c-GBM). Therefore, we performed NGS analysis to determine the
mutational status of BRAF of 13 glioblastomas (GBMs) (11 primary and 2 secondary cases) and detected one
tumor harboring the BRAF V600E mutation. We report here the detection of the BRAF V600E mutation in a patient
with c-GBM and describe the patient’s clinical course as well as the results of histopathological analysis.
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The B-Raf proto-oncogene serine/threonine kinase (B-
Raf ) is a strong activator of the extracellular signal-
regulated kinase/mitogen-activated protein kinase 1 and
2 (Erk 1/2) signal transduction cascade that mediates cell
proliferation [1]. Most BRAF mutations occur at codon
600, which resides within the activation loop of the
kinase domain, and 80% to 90% of these mutations gen-
erate a protein with a glutamic acid (E) residue
substituted for the normal valine (V) residue (BRAF
V600E). Such mutant proteins exhibit increased kinase
activity and transform cultured cells. The BRAF V600E
mutation occurs frequently in certain brain tumors such
as pleomorphic xanthoastrocytoma (PXA) (60%), PXA
with anaplastic features (60%), ganglioglioma (20% to
60%), extracerebellar pilocytic astrocytoma (20%) [2-5],
epithelioid glioblastoma (54%) [6], and giant cell glio-
blastoma (7%) [5]. However, the few studies of adult* Correspondence: yosinobu@hokuto7.or.jp
1Department of Neurosurgery, Hokuto Hospital, 7-5, Inada, Obihiro, Hokkaido
080-0039, Japan
3Department of Biology and Genetics, Laboratory of Cancer Medical Science,
Hokuto Hospital, 7-5, Inada, Obihiro, Hokkaido 080-0039, Japan
Full list of author information is available at the end of the article
© 2015 Takahashi et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.classical glioblastoma (c-GBM) with the BRAF V600E
mutation lack detailed characterization of the tumors.
Here, we present the first report, to our knowledge, that
combines histopathological, immunohistochemical, and
next-generation sequencing (NGS) analyses of c-GBM
with the BRAF V600E mutation.Case presentation
A 49-year-old man was admitted to the hospital com-
plaining of headache, vomiting, and mild left hemipar-
esis. Magnetic resonance imaging (MRI) showed a huge
multicystic mass in the right occipitoparietal area with
marked surrounding edema and a shift of the midline
structures to the left side (Figure 1A). The cyst wall and
adjacent cortical mass were enhanced with contrast
medium (Figure 1B). 18F-Fluorodeoxyglucose (FDG)
and methionine (MET) positron emission tomography
(PET) revealed high accumulation in the right occipito-
parietal area (Figure 1C, D).
Near-total resection of the tumor was performed.
After glioblastoma (GBM) was pathologically diagnosed,
the patient had local radiation using tomotherapy (60
Gy/30 fractions), with concomitant chemotherapy con-
sisting of temozolomide (75 mg/m2/day). After a 4-weekral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Magnetic resonance imaging (MRI) and positron emission tomography (PET). (A) T2-weighted image showing a huge multicystic
mass in the right occipitoparietal area with marked surrounding edema and shift of the midline structures to the left side. (B) Each cyst wall and
adjacent cortical mass was enhanced with contrast medium. (C) Fluorodeoxyglucose (FDG) PET showing high accumulation in the right occipitoparietal
area. (D) Methionine (MET) PET showing high accumulation in the right occipitoparietal area. (E, F) MRI and PET findings at the time of recurrence.
(E) Small enhanced mass adjacent to the cavity formed by removal of the tumor. (F) FDG-PET showing no accumulation in the mass. (G) MET-PET
showing high accumulation in the mass. (H) MRI 4 years after the first operation.
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lomide (150 mg/m2/day) for 5 days every 28 days. A
small contrast-enhancing lesion was seen on MRI close
to an extraction cavity 22 months after the first oper-
ation. Because MET-PET showed a high accumulation in
the mass, although none was detected using FDG-PET
(Figure 1F, G), a second operation was performed, and
the recurrence of GBM was diagnosed. Furthermore, the
patient continues to receive 31 cycles of adjuvant temo-
zolomide (200 mg/m2/day) for 5 days every 28 days and
is living without recurrence 4 years after the first oper-
ation (Figure 1H).
Pathological findings
Numerous atypical spindle cells were interspersed with
gemistocytes (Figure 2A, D), and microvascular prolifer-
ation and pseudopalisading were present (Figure 2B, C).
Tumor cells were highly positive for glial fibrillary acidic
protein (GFAP; Figure 2E), and the Ki67 index was ap-
proximately 10% (Figure 2F). Expression of cytokeratins
was undetectable in EMA+ tumor cells (Figure 2G, H).
Findings of tumor cells negative for epidermal growth
factor receptor (EGFR) but positive for P53 are typical ofsecondary GBM (Figure 2I, J). Expression of the IDH1
R132H mutant or the IDH1 R132H mutation was not
detected using immunohistochemistry or NGS analysis,
respectively (Figure 2K). In contrast, expression of the
BRAF V600E mutant was detected using immunohisto-
chemistry, and the BRAF V600E mutation was detected
using NGS (Figure 2L).
DNA extraction and NGS
DNA was extracted from formalin-fixed paraffin-
embedded (FFPE) sections using a NucleoSpin DNA
FFPE XS Kit (Macherey-Nagel, Düren, Germany), and
225 ng of each genomic DNA sample was subjected to
target amplification and library preparation for NGS
analysis using a HaloPlex Cancer Research Panel (ABL1,
JAK2, AKT1, JAK3, ALK, KIT, AR KRAS, ATM,
MAP2K1, BRAF, MAP2K4, CDKN2A, MET, CSF1R,
NOTCH1, CTNNB1, NPM1, EGFR, NRAS, ERBB2,
PDGFRA, ERBB4, PIK3CA, FANCA, PIK3R1, FANCC,
PTEN, FANCF, RET, FANCG, RUNX1, FGFR1, SMAD4,
FGFR2, SMO, FGFR3, SRC, FLT3, STK11, HRAS, TP53,
IDH1, VHL, IDH2, WT1, MAP2K2; Agilent Technologies,
Santa Clara, CA, USA) according to the manufacturer’s
Figure 2 Histopathological features of the BRAF V600E-positive glioblastoma. (A-D) Hematoxylin and eosin (H & E) staining. (A, D)
Multiple atypical spindle cells mixed with gemistocytes. (B) Microvascular proliferation, (C) pseudopalisading, (E) GFAP positive, (F) Ki67 (index
was approximately 10%), (G) EMA positive, (H) pan-cytokeratin (AE1/AE3) negative, (I) EGFR negative, (J) P53 positive, (K) IDH1 negative, and
(L) BRAF V600E positive.
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quenced using a MiSeq (Illumina, San Diego, CA, USA).
The sequence data were aligned, analyzed, and visualized
using SureCall 2.0 software (Agilent Technologies).
Immunohistochemistry
Blocks of FFPE tumor sections were cut to a thickness
of 4 μm, deparaffinized, and treated with an antigen
unmasking solution (Immunosaver, Nissin EM Co. Ltd.,Tokyo, Japan) at 90°C for 45 min and incubated with
blocking solution (3% H2O2) at room temperature. The
anti-BRAF V600E (VE1) antibody (Ventana Medical
Systems, Tucson, AZ, USA) was diluted 1:2,000 and in-
cubated with sections for 16 h at 4°C. Antibody-antigen
reactions were detected using Bond Polymer Refine
Detection reagents (Leica Biosystems, St. Louis, MO,
USA). Additional sections were incubated for 1 h at
room temperature in phosphate-buffered saline (PBS)
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anti-GFAP clone GA5, anti-Ki67 clone SP6, anti-EMA
clone E29, anti-pan-cytokeratin clone AE1/AE3, and
anti-EGFR clone 31G7 (all from Nichirei Bioscience,
Tokyo, Japan); anti-P53 antibody diluted 1:100 (Dako,
Glostrup, Denmark); or an anti-isocitrate dehydrogenase
1 (IDH1) R132H antibody clone H09 diluted 1:50
(Dianova, Hamburg, Germany). After incubation with
primary antibodies, the sections were reacted with a
peroxidase-conjugated secondary antibody (catalog num-
ber 424154, Nichirei Bioscience) for 1 h at room
temperature and rinsed with PBS. The Histofine DAB
kit (Nichirei Bioscience) was used to detect antigen-
antibody complexes.
Conclusions
The BRAF V600E mutation may occur at low frequency
in adult c-GBM. This mutation was detected by the dir-
ect sequence method of Sanger method or immunohis-
tochemistry. NGS techniques are in wide use because
mutations are detected with greater sensitivity comparedTable 1 Result of next-generation sequencing analysis of glio
Case Age Gender Type Gene
1 39 M Primary FANCA
STK11






3 60 M Primary VHL
FANCA
4 42 F Secondary FANCA
5 55 M Secondary IDH1
ATM
FANCA
6 79 M Primary FANCA
7 80 M Primary FANCA
STK11
8 80 M Primary FANCA
9 58 M Primary FANCA
STK11
10 62 M Primary FANCA
11 66 M Primary FANCA
12 63 F Primary PDGFRA
FANCA
13 62 M Primary FANCAwith Sanger sequencing [7,8]. Therefore, we have per-
formed NGS analysis to detect BRAF mutations in
tissues of 13 patients with c-GBM (11 primary and 2
secondary cases) who were treated at Hokuto Hospital.
However, the BRAF V600E mutation was detected in
only one case (7.7%; Table 1). The validity of the data is
supported by the detection of BRAF V600E in the tumor
tissue of the same patient after the tumor recurred.
When we reviewed the pathology of this case, the
tumor was not an epithelioid or a giant cell GBM be-
cause foci with glandular and ribbon-like epithelial
structures and multinucleated giant cells were not
present. Classical GBM was confirmed by two expert
neuropathologists (H.N. and S.T).
Although there is no detailed report of a BRAF
V600E-positive adult c-GBM, to our knowledge, there is
a study of two such cases [9]. The tumors of both
patients were located within the right parietal lobe.
Interestingly, the tumor of our present patient was lo-
cated in the right occipitoparietal lobe. Moreover, our
patient with BRAF V600E-positive adult c-GBM wasblastoma
ID Depth Codon Amino acid
rs2239359 264 Ggc/Agc G501S
rs59912467 157 ttC/ttG F354L
458 cCg/cGg p553R
rs121913227 311 gTg/gAg V600E
rs2239359 1,141 Ggc/Agc G501S
458 cCg/cGg p553R
rs121913227 311 gTg/gAg V600E
rs2239359 1,141 Ggc/Agc G501S
rs369018004 8,156 Ctg/Gtg L129V
rs2239359 14,888 Ggc/Agc G501S
rs2239359 9,366 Ggc/Agc G501S
rs121913500 4,571 cGt/cAt R132H
14,928 Ggt/Agt G2695S
rs2239359 18,284 Ggc/Agc G501S
rs2239359 18,284 Ggc/Agc G501S
rs2239359 3,313 Ggc/Agc G501S
rs59912467 2,723 ttC/ttG F354L
rs2239359 18,161 Ggc/Agc G501S
rs2239359 18,161 Ggc/Agc G501S
rs59912467 2,723 ttC/ttG F354L
rs2239359 513 Ggc/Agc G501S
rs2239359 8,387 Ggc/Agc G501S
rs2228230 2,959 gtC/gtT V824
rs2239359 7,658 Ggc/Agc G501S
rs2239359 8,036 Ggc/Agc G501S
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the first operation. In contrast, the patients studied by
Chi et al. [9] survived for 19 and 36 months. The IDH1
mutation serves as a good prognostic factor for patients
with GBM but was not detectable using NGS or immu-
nohistochemical analyses. These data are consistent with
the results of a study of two patients with BRAF V600E-
positive c-GBM [9].
Although the number of patients was small, these
three patients with BRAF V600E-positive GBM survived
relatively longer compared with patients without this
mutation. Therefore, tumors with the BRAF V600E mu-
tation may represent a more favorable subtype of GBM.
More patients with GBM must be analyzed to conclude
that the BRAF V600E mutation is a potential prognostic
marker for GBM. Moreover, inhibitors of B-Raf protein
kinase activity may serve as efficacious drugs for treating
patients with BRAF V600E-positive GBM [10,11]. There-
fore, we suggest that we should perform routine genetic
testing of BRAF V600E mutation, which might provide
effective alternatives to treat patients with GBM.
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